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Abstract
AIM: To evaluate the role of microRNA (miR)-146a, 
-155 and -122 in the duodenal mucosa of pediatric 
patients with Crohn’s disease (CD) and the effect of 
transforming growth factor-β (TGF-β) on these miRs in 
duodenal epithelial and fibroblast cells.
METHODS: Formalin-fixed, paraffin-embedded 
biopsies derived from the macroscopically inflamed 
(CD inflamed: n  = 10) and intact (CD intact: n  = 10) 
duodenal mucosa of pediatric CD patients and control 
children (C: n  = 10) were examined. Expression of 
miR-146a, -155 and -122 was determined by real-
time polymerase-chain reaction (PCR). The expression 
of the above miRs was investigated in recombinant 
human TGF-β (1 nmol/L, 24 h) or vehicle treated 
small intestinal epithelial cells (CCL-241) and primary 
duodenal fibroblast cells derived from healthy children 
as well.
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Basic Study
Increased duodenal expression of miR-146a and -155 in 
pediatric Crohn’s disease
INTRODUCTION
Crohn’s disease (CD) is a chronic immune-mediated 
disorder, which is frequently characterized by the 
appearance of lesions in the upper gastrointestinal 
(GI) tract, primarily in pediatric patients[1,2]. In adults, 
upper GI lesions in the cardiac area with bamboo joint-
like appearance[3] are regarded to be significant risk 
factors for the progression of the disease from the 
inflammatory to stenotic or penetration form of CD[4]. 
In the pathogenesis of CD, epigenetic factors 
including microRNAs (miRs) have come into focus as 
potent modulators of the progression of the disease. 
An increasing number of studies investigates the role 
of these short single-stranded RNAs in inflammatory 
bowel disease (IBD)[5-11]; however, the expression 
profile of miRs in the upper GI region of CD patients is 
completely unknown. 
The aim of the present study was to investigate the 
mucosal expression of miR-146a, -155 and -122 in the 
upper GI tract of children with CD, and to examine the 
effect of the anti-inflammatory transforming growth 
factor (TGF)-β on the expression of the investigated 
miRs. These miRs affect a number of key biological 
functions involved in the pathomechanism of CD, 
including inflammatory response, intracellular signaling 
cascades and response to the presence of bacteria[5].
However, upper GI tract endoscopy is an important 
tool to diagnose CD in pediatric patients, recently there 
have been no specific markers to definitely distinguish 
it from other GI diseases with erosions, ulcerations 
[Helicobacter pylori (H. pylori) infection, peptic ulcer 
caused by an infection or medication, or eosinophil 
gastritis], and disorders with granulomas (sarcoidosis, 
Mycobacterium tuberculosis). Therefore, we suppose 
that our results may contribute to the identification of 
potential novel biomarkers or therapeutic targets of 
CD.
MATERIALS AND METHODS
Patients
CD was diagnosed according to the Porto criteria[12,13]. 
The disease activity score was assessed regarding the 
Pediatric CD Activity Index (PCDAI). Control children 
were referred to the outpatient clinic due to recurrent 
abdominal pain and GI symptoms to exclude organic 
diseases. Esophago-gastro-duodenoscopy was part of 
their diagnostic procedure showing normal macroscopic 
appearance and histology. Duodenal biopsy samples 
were taken from different patients, macroscopically 
inflamed (CD inflamed: n = 10) and non-inflamed (CD 
intact: n = 10) regions of the duodenal mucosa from 
children with CD and controls (C: n = 10). Biopsies 
were immediately fixed in buffered formaldehyde and 
embedded into paraffin (PF). Clinical characteristics 
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RESULTS: Expression of miR-146a was significantly 
higher in the inflamed duodenal mucosa compared to 
the intact duodenal mucosa of children with CD (CD 
inflamed: 3.21 ± 0.50 vs  CD intact: 0.62 ± 0.26, p ≤ 
0.01) and to the control group (CD inflamed: 3.21 ± 
0.50 vs  C: 1.00 ± 0.33, p ≤ 0.05). The expression of 
miR-155 was significantly increased in the inflamed 
region of the duodenum compared to the control group 
(CD inflamed: 4.87 ± 1.02 vs  Control: 1.00 ± 0.40, p 
≤ 0.001). The expression of miR-122 was unchanged 
in the inflamed or intact mucosa of CD patients 
compared to controls. TGF-β treatment significantly 
decreased the expression of miR-155 in small intestinal 
epithelial cells (TGF-β: 0.7 ± 0.083 vs  Control: 1 ± 
0.09, p  ≤ 0.05) and also the expression of miR-146a 
(TGF-β: 0.67 ± 0.04 vs  Control: 1 ± 0.15, p  ≤ 0.01) 
and miR-155 (TGF-β: 0.72 ± 0.09 vs  Control: 1 ± 0.06, 
p ≤ 0.05) in primary duodenal fibroblasts compared to 
corresponding vehicle treated controls. TGF-β treatment 
did not influence the expression of miR-122.
CONCLUSION: The elevated expression of miR-
146a and -155 in the inflamed duodenal mucosa of 
CD patients suggests the role of these miRs in the 
pathomechanism of inflammatory bowel disease. Anti-
inflammatory TGF-β plays an important role in the 
regulation of the expression of these miRs.
Key words: Inflammatory bowel disease; Crohn’s 
disease; Pediatric; MicroRNAs; transforming growth 
factor-β
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Recent evidence suggests that besides the 
genetic basis, epigenetic factors including microRNAs 
(miRs) also act as potent inflammatory modulators 
during the pathogenesis of inflammatory bowel 
disease. MiR expression in the upper-gastrointestinal 
tract of pediatric patients with Crohn’s disease (CD) 
has not yet been analyzed. Moreover, the relation of 
transforming growth factor-β, playing a prominent 
role in the pathomechanism of CD, to miRs in this 
setting is also unknown. The description of precise 
miR patterns specific for the different segments of the 
gastrointestinal tract may contribute to the introduction 
of novel diagnostic markers and to the identification of 
potential therapeutic targets.
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of patients with CD and controls are shown in Table 
1. Written informed consent was obtained from the 
parents prior to the procedure, and the study was 
approved by the Semmelweis University Regional and 
Institutional Research Ethics Committee (TUKEB No.: 
10408/2012).
TGF-β treatment of duodenal epithelial cells and primary 
fibroblasts
Normal small intestinal epithelial cells (CCL-241, 
American Type Culture Collection, Manassas, VA, 
United States) were grown in HybriCare medium 
(American Type Culture Collection, Manassas, VA, 
United States) supplemented with 10% fetal bovine 
serum (FBS) (Invitrogen, Carlsbad, CA, United States), 
30 ng/mL epidermal growth factor (R&D Systems, 
Minneapolis, MN, United States), and 1% Penicillin and 
Streptomycin mixture (Sigma-Aldrich Co., St. Louis, 
MO, United States). Epithelial cells were grown under 
standard cell culture conditions (37 ℃, humidified, 5% 
CO2/95% air environment). 
Based on the previously described method, primary 
duodenal fibroblast cells were freshly isolated[14] from 
the duodenal mucosa of healthy children. Briefly the 
biopsies were washed in phosphate-buffered saline 
(PBS) and homogenized in 1 mg/mL collagenase 
content PBS (Sigma-Aldrich Co., St. Louis, MO, United 
States). Cells were grown in Dulbecco’s Modified Eagle 
Medium supplemented with 1% FBS (Invitrogen, 
Carlsbad, CA, United States) and 1% Penicillin and 
Streptomycin mixture. Cells were grown under standard 
cell culture conditions (37 ℃, humidified, 5% CO2/95% 
air environment) until a confluent monolayer was 
obtained. During culturing, the unattached cells were 
removed after every 24 h culture period.
Epithelial and primary fibroblast cells were seeded 
into 6-well plates at a density of 5 × 105 cells/well 
and treated for 24 h with recombinant human TGF-β 
(R&D Systems, Minneapolis, MN, United States) at a 
concentration of 1 nmol/L or vehicle only for control cells.
RNA isolation
Total RNA was isolated from formalin-fixed, paraffin-
embedded biopsies using RNeasy Minikit (Qiagen, 
Düsseldorf, Germany) after removing paraffin from 
the samples according to the instructions of the manu-
facturer. All contaminants were efficiently washed away, 
DNase was used to remove DNA from the samples 
using on-column DNase treatment. Concentrated RNA 
was filtrated using RNeasy MinElute spin columns 
(Qiagen, Düsseldorf, Germany). RNA was eluted in 30 µL 
water. 
Total RNA of the intestinal epithelial and fibroblast 
cells was isolated by the Quick-RNA MiniPrep isolation 
kit (Zymo Research, Irvine, CA, United States) 
according to the instructions of the manufacturer. 
RNA Lysis Buffer purified the RNA using Zymo-Spin™ 
Columns. All contaminants were washed away (RNA 
Prep and Wash Buffer) and DNase was used to remove 
the DNA from the samples. RNA was eluted in 30 µL 
water and used further immediately.
Reverse transcription and real-time polymerase-chain-
reaction
The total RNA was reversely transcribed by the 
TaqMan MicroRNA Reverse Transcription kit (Applied 
Biosystems - ABI, Foster City, CA, United States). 
TaqMan MicroRNA Assay (Applied Biosystems - ABI, 
Foster City, CA, United States) was used to quantify 
individual microRNA levels with real-time Reverse 
transcription and real-time polymerase-chain-reaction 
(RT-PCR) on a LightCycler 480 instrument (Roche 
Diagnostics, Basel, Switzerland). Reactions were 
performed in triplicates. Relative expression of miRs 
was determined by the 2ΔCq method using U6 as an 
internal control.
Statistical analysis
Statistical analysis was performed by Graphpad 
statistical software package (Graphpad Software, 
La Jolla, CA, United States). Normality was tested 
by the Shapiro-Wilk test. Analysis was based on the 
Mann-Whitney U-test, Kruskal-Wallis-test, Analysis of 
variance (ANOVA) and Dunn’s Post-Hoc test, and p ≤ 
0.05 was considered as statistically significant. Data 
were presented as mean ± SE.
RESULTS
Expression of miR-146a in the duodenal mucosa of 
pediatric patients with CD
The expression of miR-146a was significantly higher 
in the inflamed duodenal mucosa of children with CD 
compared to the intact mucosa (CD inflamed: 3.21 ± 
0.50 vs CD intact: 0.62 ± 0.26, p ≤ 0.01) and controls 
(CD inflamed: 3.21 ± 0.50 vs Control: 1.00 ± 0.33, p 
≤ 0.05). There was no significant difference between 
the uninflamed group and the control one (CD intact 
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Table 1  Clinical characteristics of patients
Control CD intact CD inflamed
n 10 10 10
Age 8.75 ± 2.36 12.4 ± 1.52 12.11 ± 1.63
Gender 2f/8m 5f/5m 2f/8m
BMI (kg/m2) 20.07 ± 2.64 14.83 ± 0.8 18.64 ± 1.81
PCDAI 0    21.94 ± 4.37c  16.11 ± 3.51b
Iron (µmol/L) 15.83 ± 2.53      4.89 ± 0.84b    8.33 ± 2.61a
TIBC (µmol/L)   60.4 ± 2.71     48.5 ± 2.64 59.71 ± 8.70
Albumin (g/L) 47.33 ± 1.31   38.67 ± 1.62   48.4 ± 5.56
Hemoglobin (g/L) 132.8 ± 6.72    113.1 ± 4.02a 124.4 ± 5.93
Hematocrit (%)   0.38 ± 0.02   0.344 ± 0.01   0.37 ± 0.02
Platelet count (Giga/L)   365.5 ± 30.29      517.1 ± 34.62a   416.7 ± 63.77
aP ≤ 0.05, bP ≤ 0.01, cP ≤ 0.001 vs Control. BMI: Body mass index; CD: 
Crohn’s disease; PCDAI: Pediatric Crohn’s disease activity index; TIBC: 
Total iron binding capacity.
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± 0.38 vs Control: 1.00 ± 0.40, p = N.S.) (Figure 1B).
Expression of miR-122 in the duodenal mucosa of 
pediatric patients with CD
There was no significant difference in the expression 
of miR-122 between the CD and control groups 
(CD inflamed: 0.86 ± 0.25, CD intact: 0.96 ± 0.14, 
Control: 1.00 ± 0.28, p = N.S.) (Figure 1C).
Expression of miR-146a, -155 and -122 in TGF-β treated 
duodenal epithelial cells
TGF-β had no effect on the expression of miR-146a (p 
= N.S., Figure 2A); however, it decreased significantly 
the expression of miR-155 in CCL-241 small intestinal 
epithelial cells (TGF-β: 0.7 ± 0.083 vs Control: 1 ± 
0.09, p ≤ 0.05) (Figure 2B). No miR-122 was detected 
in the small intestinal epithelial cells.
Expression of miR-146a, -155 and -122 in TGF-β treated 
duodenal fibroblasts
TGF-β significantly decreased the expression of miR-
146a (TGF-β: 0.67 ± 0.04 vs Control: 1 ± 0.15, p ≤ 
0.01) (Figure 3A) and miR-155 (TGF-β: 0.72 ± 0.09 vs 
Control: 1 ± 0.06, p ≤ 0.05) (Figure 3B) in duodenal 
fibroblasts compared to vehicle treated control cells. 
There was no difference in the expression of miR-122 
vs Control: p = N.S.) (Figure 1A).
Expression of miR-155 in the duodenal mucosa of 
pediatric patients with CD
miR-155 showed significantly elevated expression in 
the inflamed region of the duodenal mucosa of CD 
patients compared to the control group (CD inflamed: 
4.87 ± 1.02 vs Control: 1.00 ± 0.40, p ≤ 0.001). 
There was no significant difference between the 
uninflamed group and the control one (CD intact: 2.50 
6030 July 14, 2016|Volume 22|Issue 26|WJG|www.wjgnet.com
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Figure 1  Expression of microRNA-146a (A), microRNA-155 (B) and 
microRNA-122 (C) in the duodenal mucosa of pediatric patients with 
Crohn’s disease. Expression of microRNA (miR)-146a was significantly 
higher in the inflamed duodenal mucosa of children with Crohn’s disease (CD) 
compared to the intact mucosa and controls. miR-155 showed significantly 
elevated expression in the inflamed region of the duodenum compared to the 
control group. There was no significant difference in the expression of miR-122 
between the groups. aP ≤ 0.05 vs Control; bP ≤ 0.001 vs Control; dP ≤ 0.01 vs 
CD intact.
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Figure 2  Effect of transforming growth factor-β on the expression of 
microRNA-146a (A), and microRNA-155 (B) in duodenal epithelial cells. 
Transforming growth factor (TGF)-β did not have any effect on the expression 
of microRNA (miR)-146a. TGF-β significantly decreased the expression of 
miR-155. There was no miR-122 expression detected, aP ≤ 0.05 vs Control.
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when TGF-β was administered compared to the control 
group (p = N.S., Figure 3C).
DISCUSSION
In the present study, we demonstrated the elevated 
expression of miR-146a and -155 in the macrosco-
pically inflamed duodenal mucosa of newly diagnosed, 
treatment-naive pediatric patients with CD compared 
to the control group for the first time. These results 
are in accordance with our previous observations 
demonstrating the increased expression of miR-146a 
and -155 in the inflamed colonic region of pediatric 
IBD patients. However, in contrary to our earlier 
observations related to the colon, we found unchanged 
expression of miR-122 in the duodenal mucosa of 
children with CD[5].
According to the criteria of the “Porto” IBD Working 
Group of the European Society for Pediatric Gastro-
enterology, Hepatology and Nutrition (ESPGHAN), upper 
GI tract endoscopy is recommended to be performed to 
identify lesions in all children irrespective of presence 
or absence of upper GI symptoms[15]. Based on the 
Hungarian Pediatric IBD Registry Group (HUPIR), 
upper GI tract abnormalities were found in 64% and 
40% of children with CD and UC, respectively[16]. 
Characteristic findings (ulcers, erosions, aphthous 
lesions, and granulomas) were noted in about one 
third of children with CD; moreover, upper GI tract 
endoscopy was advantageous in establishing the 
final diagnosis in 9% of children with CD (diagnostic 
yield)[16]. However, to the best of our knowledge, 
there is no specific marker to clearly diagnose CD in 
the upper GI tract and to distinguish it from H. pylori 
infection, eosinophilic enteropathy or drug-induced 
lesions. Moreover, H. pylori-negative chronic active 
gastritis appears frequently in adult patients with 
CD, which is hard to differentiate from CD lesions[17]. 
Therefore, the aim of our present study was to 
establish a duodenum-specific miR pattern in pediatric 
patients with CD, which could facilitate the deeper 
understanding of the pathomechanism of IBD, and it 
may serve as a diagnostic tool in the future.
Recently miR-146a, -155 and -122 have come 
into focus as potential regulators of the inflammatory 
response, intracellular signaling cascades, regulation 
of cytokine production and response to bacteria, all of 
which play an important role in IBD. The main findings 
of the previous studies regarding to the expression of 
miR-146a, -155 and -122 in the GI tract of adult and 
pediatric IBD patients also confirm it. Based on these 
results and our present findings, we can conclude 
that independently of the localization of the intestinal 
inflammatory regions (colon, rectum, or duodenum), 
the expression of miR-146a and -155 was elevated 
in patients with CD suggesting that these miRs are 
rather inflammation- than region-specific[5,8,18-26]. Both 
in vivo and in vitro studies confirm that miR-146a and 
-155 have opposite effects during inflammation. While 
miR-155 is a promoter of inflammation, miR-146a is a 
mediator of immune suppressive responses[27,28].
In contrary to miR-146a and -155, different 
expression pattern of miR-122 has been demonstrated 
throughout the GI tract. Previously we observed 
elevated expression of miR-122 in the intact colonic 
region of pediatric CD patients[5], but in the present 
study we found no difference in the duodenal miR-122 
expression between CD patients and the control ones. 
Chen et al[29] have found that miR-122 may decrease 
intestinal injury by suppressing the NOD2-induced NF-
κB signaling pathway. On the contrary, overexpression 
of miR-122 in enterocytes have resulted in the mRNA 
degradation of occludin leading to disturbed tight-
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Figure 3  Effect of transforming growth factor-β on the expression of 
microRNA-146a (A), microRNA-155 (B), and microRNA-122 (C) in duodenal 
fibroblasts. Transforming growth factor (TGF)-β significantly decreased the 
expression of microRNA (miR)-146a and miR-155. TGF-β had no effect on the 
expression of miR-122, aP ≤ 0.05 vs Control, bP ≤ 0.01 vs Control.
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junction integrity and increased intestinal permeability, 
which are important processes in the pathogenesis of 
IBD[30,31].
Inflammatory factors have been shown to modulate 
the expression of miRs, but the potential regulators of 
miR-146a, -155 and -122 in IBD are largely unknown. 
One of the known key modulators of inflammatory 
responses is anti-inflammatory TGF-β[32-34].
In case of IBD, increased expression of TGF-β 
was demonstrated in the inflamed intestinal regions. 
However, due to the reduced level of phosphorylated 
mothers against decapentaplegic homolog (SMAD)3 
and diminished complex formation with SMAD4, 
the TGF-β-mediated signaling is insufficient in IBD 
patients[35].
Moreover, elevated level of SMAD7, the known 
endogenous inhibitor of TGF-β signaling, contributes 
to the enhanced production of pro-inflammatory 
cytokines resulting in the maintenance of inflammation 
in IBD[36,37]. This disadvantageous effect of SMAD7 
in IBD is proved by its inhibition in a human phase 
Ⅱ study. In fact, the oral administration of SMAD7 
targeting antisense oligonucleotides has led to clinical 
remission in 60% of adult CD patients[38]. Moreover, 
Rho proteins, which are also connected to the TGF-β 
signaling pathway are involved in the regulation of 
IBD. Previous studies have reported Ras homolog 
gene family member A (RhoA) protein activation in CD 
patients. RhoA is involved in inflammation through the 
activation of the NF-κB, IL-1β and the TNF-α pathway, 
regulation of cell adhesion, migration, phagocytosis, 
and proliferation[39,40] (Figure 4).
Based on these key effects of TGF-β in the patho-
mechanism of IBD, we also aimed to investigate the 
possible link between TGF-β and miR-146a, -155 
and -122. Following TGF-β treatment, we observed 
downregulation of miR-155 in both small intestinal 
epithelial and primary duodenal fibroblast cells 
and reduced expression of miR-146a in duodenal 
fibroblasts. However, TGF-β had no effect on the 
expression of miR-122 either in epithelial or in fibroblast 
cells.
Previous studies have confirmed the effect of these 
miRs on the TGF-β-mediated signaling pathway[41-49] 
(Figure 4). In chondrocytes, fetal femur derived 
skeletal stem cells and gastric cancer cells miR-146a 
negatively regulates the expression of SMAD 2/3 and 
SMAD4, while in monocyte, cervical and prostate 
cancer cells miR-155 negatively modulates SMAD2/3, 
the key mediators of TGF-β-induced effects[46,47,49,50]. 
Moreover, the ectopic expression of miR-155 and 
-122 has significantly reduced the expression of RhoA 
indicating the role of these miRs in the TGF-β-induced 
epithelial-mesenchymal transition, cell migration and 
invasion, as well[41,43].
In conclusion, increased expression of miR-146a 
and -155 in the inflamed intestinal mucosa suggests 
their involvement in the pathomechanism of CD as 
inflammation-specific markers. Our results suggest that 
the expression of miR-146a and -155 is independent 
of and that of miR-122 is dependent on the localization 
of CD. Moreover, anti-inflammatory TGF-β is a negative 
regulator of miR-146a and -155 in small intestine 
epithelial and primary duodenal fibroblast cells. Our 
recent data have provided a baseline to explore the 
possible role of these miRs as diagnostic markers or 
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Figure 4  Schematic representation of the target interactions between transforming growth factor-β - microRNA-146a, -155 and -122. Transforming growth 
factor (TGF)-β is considered to be a major anti-inflammatory cytokine playing an important role in the pathogenesis of inflammatory bowel disease. MicroRNA 
(miR)-146a, -155 and -122 act as possible regulators of the TGF-β signal transduction, with capacity to induce apoptosis, cell migration, invasion and proliferation. 
Moreover, TGF-β induces and represses the transcription of various genes. Data shown in the figure are based on MiRTarBase Database. SMAD: Mothers against 
decapentaplegic homolog; RhoA: Ras homolog gene family, member A.
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characterized by lesions of the upper gastrointestinal (GI) tract, primarily in 
pediatric patients. Recently, epigenetic factors including microRNAs (miRs) 
have come into focus as potent modulators of the progression of the disease. 
An increasing number of studies investigate the role of these short single-
stranded RNAs in inflammatory bowel disease (IBD); however, the expression 
profile of miRs in the upper GI region of pediatric CD patients is completely 
unknown.
Research frontiers
In the previous study, the authors observed increased expression of miR-146a, 
-155 and -122 in the inflamed colonic region of pediatric IBD patients. 
Innovations and breakthroughs
This is the first study investigating the mucosal expression of miR-146a, -155 
and -122 in the upper GI tract of children with CD and examining the effect of 
anti-inflammatory transforming growth factor (TGF)-β on their expression of 
small intestinal epithelial and primary duodenal fibroblast cells.
Applications
Increased expression of miR-146a and -155 in the inflamed intestinal mucosa 
of pediatric patients with CD suggests their involvement in the pathomechanism 
of CD as inflammation-specific markers. Anti-inflammatory TGF-β is a negative 
regulator of miR-146a and -155 in the small intestinal epithelial and primary 
duodenal fibroblast cells. The recent data provide a baseline to explore the 
possible use of these miRs as diagnostic markers or their potential role as 
therapeutic targets.
Terminology
MiRs are 19-24 nucleotide-long single-stranded RNAs involved in the regulation 
of gene expression at transcriptional and posttranscriptional level. MiRs play a 
determining regulatory role in innate and adaptive immune processes.
Peer-review
The authors demonstrated an interesting study based on their previous findings 
connected to the expression of miR-146a, -155 and -122 in the colonic mucosa 
of pediatric inflammatory bowel disease. It would be interesting to measure the 
effect of the pro-inflammatory tumor-necrosis-factor-α on the small intestine 
epithelial and primary duodenal fibroblast cells as a future plan.
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